February 1, 2012

We’ve moved!  To view the latest New Cambridge Observer posts,  please click here!  http://newcambridgeobserver.com.

–Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group, specializing in public relations, thought leadership and social media for clients in health, science and technology, worldwide.

Advertisements

Here’s a summary, compiled by the stats helper monkeys at WordPress.com, who mulled over how this blog did in 2010. Five thousand views… Thanks, wordpress,  readers, and the Boston Globe!  I promise to be more diligent in 2011.

Here’s a high level summary-followed by a rundown by individual blog. Anita

Healthy blog!

The Blog-Health-o-Meter™ reads Fresher than ever.

Crunchy numbers

Featured image

A Boeing 747-400 passenger jet can hold 416 passengers. This blog was viewed about 4,700 times in 2010. That’s about 11 full 747s.

 

In 2010, there were 6 new posts, growing the total archive of this blog to 57 posts. There were 40 pictures uploaded, taking up a total of 6mb. That’s about 3 pictures per month.

The busiest day of the year was January 6th with 203 views. The most popular post that day was Eeek! May I borrow your cat? Mice. Please advise. .

Where did they come from?

The top referring sites in 2010 were digg.com, healthfitnesstherapy.com, dating-online2u.blogspot.com, slashingtongue.com, and the-best-twitter.com.

Some visitors came searching, mostly for new cambridge observer, cambridge observer, unusual playground, cambridge common playground, and fruits and vegetables.

Attractions in 2010

These are the posts and pages that got the most views in 2010.

1

Eeek! May I borrow your cat? Mice. Please advise. December 2009
26 comments

2

New Cambridge Playground Opens September 2009

3

Essaydi’s Les Femmes du Maroc a must-see. January 2010

4

Ladino Music Group Aljashu Debuts in Boston December 2009

5

Non-invasive test predicts risk of sudden cardiac arrest March 2009

We’ve changed hosts, which seems to have confused the search engines. You can find New Cambridge Observer at http://newcambridgeobserver.com  –or email us at harriscom at comcast.net.   Sorry for any mixup. Anita  Harris

New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA. We also publish Harriscom Blog and Ithaca Diaries Blog.

I’m  helping Cambridge Heart and Kogs Communications get out the good news that the company’s non-invasive test, which is administered much like a stress test, on a treadmill, accurately predicts the risk of sudden cardiac arrest–the leading killer in the US.

Here’s today’s release:

Tewksbury, Mass., March 3, 2009 – Cambridge Heart, Inc. (OTCBB-CAMH), today announced the publication of five articles supporting the use of Microvolt T Wave Alternans™ (MTWA) testing in a supplement to the March issue of the Heart Rhythm journal. Featured in the supplement is a comprehensive meta-analysis of 6,000 patients confirming the value of MTWA as a non-invasive marker of risk for sudden cardiac arrest (SCA).

The MTWA test, administered much like a stress test on a treadmill, was developed by Cambridge Heart as a diagnostic tool to help physicians determine a patient’s risk of sudden cardiac arrest — the leading cause of death in the United States.

The meta-analysis, conducted by a group led by Stefan Hohnloser, MD, FHRS, of the JW Goethe University Division of Cardiology in Frankfurt, Germany, assessed 13 MTWA clinical studies involving approximately 6,000 cardiac patients.

“The results demonstrate that MTWA testing is a consistently accurate predictor of sudden cardiac death and cardiac arrest in patients who do not already have implantable cardiac defibrillators (ICDs),” said Dr. Stefan Hohnloser. “These are the patients for whom MTWA testing is intended.”

The meta-analysis authors also conclude that:

· Patients who test negative for MTWA abnormalities are at extremely low risk (0.3%) for SCA in the next 12 months.

· MTWA testing can help doctors guide ICD therapy to appropriate patients and overcome the widespread reluctance of patients and referring physicians to accept ICD therapy.

· In clinical trials, appropriate ICD shocks are an unreliable surrogate endpoint for SCA and can skew results of risk stratification studies.

“This comprehensive analysis confirms the findings of numerous peer-reviewed studies which underscore the important role of MTWA in assessing a patient’s risk of sudden cardiac arrest,” said Ali Haghighi-Mood, PhD, Chief Executive Officer of Cambridge Heart.

The Heart Rhythm supplement also includes:

· A second meta-analysis of MTWA testing in patients with non-ischemic heart disease, authored by Gaetano De Ferrari, MD and Antonio Sanzo, MD of the Department of Cardiology at Fondazione IRCCS Policlinico San Matteo, Pavia Italy. Analyzing eight available trials involving 1,450 patients, the paper indicates that in this population negative MTWA results can help patients and their physicians decide whether ICD therapy may safely be avoided.

· An article by Michael J. Mirro, MD, Medical Director of the Parkview Health System Clinical Research Center in Fort Wayne Indiana, who describes how his center has incorporated MTWA testing into clinical practice to complement other methods for identifying and educating patients about the risk of SCA.

· A review of numerous studies concerning the underlying cellular mechanisms of T-wave alternans. The authors conclude that microvolt T-wave alternans is a marker of cellular changes that make the heart susceptible to sudden cardiac arrest. The review was carried out by Michael Cutler, DO, PhD, and David S. Rosenbaum, MD, of the Heart and Vascular Research Center at the Department of Biomedical Engineering at Case Western Reserve University in Cleveland.

· A review by Navinder Sawhney, MD and Sanjiv Narayan, MD of the University of California at San Diego that underscores the value of MTWA testing in patients who have had heart attacks but do not fall within current guidelines for ICD implantation.

The articles in the supplement can be found on the Heart Rhythm journal website at:

http://www.heartrhythmjournal.com/issues/contents?issue_key=S1547-5271(09)X0006-8

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans measurement technologies including the patented Analytic Spectral Method® and ultrasensitive disposable electrode sensors. Medicare reimburses the Analytic Spectral Method® under its National Coverage Policy. Cambridge Heart, founded in 1990, is based in Tewksbury, MA. The company’s Microvolt T-Wave Alternans™ (MTWA) test, developed by Cambridge Heart (OTCBB: CAMH), is based on research originally conducted at the Massachusetts Institute of Technology. http://www.cambridgeheart.com.

Statements contained in this press release are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to achieve broad market acceptance of the Company’s MTWA technology, failure of our sales and marketing organization to market our products effectively, inability to hire and retain qualified clinical applications specialists in the Company’s target markets, failure to obtain or maintain adequate levels of third-party reimbursement for use of the Company’s MTWA test, customer delays in making final buying decisions, decreased demand for the Company’s products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology and other factors identified in our most recent Annual Report on Form 10‑K/A under “Risk Factors”, which is on file with the SEC and available at http://www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.

The New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA.

Thought you might like to know that my client, Scientia Advisors, is offering five free Webinars aimed at helping major corporations, emerging companies and innovative startups choose strategic directions.

The Webinars, in February, 2009, will present Scientia’s latest industry reviews. The reviews are based on interviews with scientists, clinicians, manufacturers, and product developers as well as on traditional market research.

The Webinars will initially be presented live, with opportunities for interactive participation.  Less-detailed Webcasts will subsequently be available for download from the Scientia Advisors Web site.

Here’s the schedule; click on any of the titles for more information or to register.
Anita


· Riding the High Value In Vitro Diagnostics Wave: Translating Promise Into Clinical Reality With Managing Partner Harry Glorikian, 11 AM Tuesday, February 10

· Back to the Future: Cell Market Entrance Strategies, Post-Stem Cell Deregulation

With Partner Arshad Ahmed, 11 AM Wednesday, February 11

· Drivers of Success in Functional Foods
With Principal Bob Jones 2 PM Wednesday, February 11

· Molecular Diagnostics: Identifying Candidates for Success in an Innovation-Driven Market

With Harry Glorikian, 11 AM Thursday, February 12

· Point of Care: Enabling Broad Product Adoption Through Maximized Access to Health Care Sites
With Harry Glorikian, 11 AM Thursday, February 19

Scientia Advisors, based in Cambridge, MA and Palo Alto, CA, is an international management consulting firm specializing in growth and operational strategies for major and emerging companies in health care, life science and biotechnology.

New Cambridge Observer is a publication of the Harris Communications Group, of Cambridge, MA.

With the ever increasing fall of bookstores and impending newspaper layoffs, I’d like to echo Alex Beam’s call for readers to reach for their wallets.

In case you missed his January 9 column, “Closing Costs,” in the Boston Globe, it opens: “Here is a dispatch from the Land of No Suprises: Bookstores–buffed by the recession, by Amazon, by electronic reading devices–are closing their doors”. He points out that, easy as it is to go to Amazon for books and read newspapers online for free, by behaving normally, “you kill the things you love.”

In Boston, after several waves of reporter buyouts, people keep telling me that they’ve dropped their subscriptions to the Globe because it’s gone downhill, and, anyway, they can get it on line, for free. Duh.

My apologies for stating the obvious, but many of my friends don’t seem to get that, in  a vicious financial cycle,  with fewer paying customers,   the paper can get fewer advertisers, revenues go down, and, as a result, the Globe and many other papers have had to  “encourage”  their most senior,  talented reporters to leave.  The Globe announced  a new round of editorial layoffs just last week.

I’ll be writing more about this–but for the time being, please support the  free press–by paying for it.

The New Cambridge Observer is a publication of the Harris Communications Group, of Cambridge, MA.